

Rapid Defense Inc.

# Transforming Healthcare with Cutting-Edge Biotech Innovations

---

Telephone  
+1 (858) 344-9778

Website  
[www.rapiddefenseinc.com](http://www.rapiddefenseinc.com)

# Problem Statement

## The Challenge

Diseases like colds, flu, respiratory infections, and cancer impact millions worldwide, with current solutions often limited in effectiveness or causing side effects

## Real-World Impact

- Immune system vulnerabilities lead to higher susceptibility to infections and diseases.
- Research suggests ImmunoFolate may have potential in fighting cancer cells, pending clinical trials.

## Market Scope

High global demand for effective, science-backed immune health solutions in both pharmaceutical and nutraceutical markets.

# Solutions

## Introducing ImmunoFolate (ImmunoPterin)

A patent-pending immunomodulatory supplement designed to enhance immune function naturally.

### How It Works

- Stimulates IL-10, the master cytokine, while reducing inflammatory cytokines (IL-1, IL-6).

### Benefits

- No reported side effects.
  - Affordable and convenient for daily use.
  - Demonstrated faster recovery from illnesses.
-

# Competitive Advantage

## ImmunoFolate vs. Current Solutions

- ImmunoFolate: Safe, no drug interactions, affordable, case studies show 100% efficacy.
- Competitors: Often accompanied by side effects, high costs, and slower recovery speeds.

## Clinical Results

- Recovery times: 48 hours for respiratory illnesses, 30 hours for colds and flu.
  - Users reported 0% incidence of respiratory infections when taken preventatively.
-

# Traction and Progress

## Research and Case Studies

- Published in peer-reviewed journals [e.g., Moheno, Phillip B. B. and Fuchs, Dietmar. "Immunopterine: A prospective therapy and preventative to fight COVID-19?" *Pteridines*, vol. 33, no. 1, 2022, pp. 11-20. <https://doi.org/10.1515/pteridines-2022-0038>]
- Demonstrated effectiveness during global health crises.

## Regulatory Status

- Active ingredients are to be fully regulated by the US FDA.

## Intellectual Property

- Patent-pending status ensures competitive advantage.
-

# Team

## Core Team Expertise

- Phillip B.B. Moheno, PhD: Founder, immunology and supplement innovator.
- Dietmar Fuchs, PhD – Biochemist, Innsbruck Medical University: Pioneer in immunological marker research and diagnostic innovations.
- Majd Oteibi, MD, DHSc, MAS, CCRP, FRSPH, Validus Institute Inc. CEO/ Director of Clinical Research
- Yousef Jasemian, ND, PhD: Expertise in integrative therapies and patient-centric drug development.
- Abby Lindsay, BSN: Specialist in clinical trial management with hands-on nursing expertise.
- Heldimar Fernandez, RN, BSN: Oncology nursing veteran with a focus on patient care optimization.



## Team

### Core Team Expertise

- Edgar Berkey, PhD, MBA: Leader in biotech commercialization strategies.
- Stephen Chang, PhD – SanRx Consultant: Decades of experience in drug discovery and preclinical trials.
- Boris Minev, MD – Director of Tumor Immunology, UCSD Moores Cancer Center: Cutting-edge research in oncology and tumor immunology.
- James C. Ryan, PhD – UC San Francisco: Authority on immunological pathways and therapeutic targeting.
- Arnold L. Rheingold, PhD – UC San Diego: Expert in structural chemistry for pharmaceutical applications.
- Antonio G. DiPasquale, PhD – UC Berkeley: Specialist in molecular dynamics and drug-receptor interactions.
- John D. Morrey, PhD – Institute for Antiviral Research, Utah State University: Acclaimed researcher in antiviral drug mechanisms.
- Daniel F. Hoft, MD, PhD – Saint Louis Univ.: Expert in immunotherapy and vaccine development.
- Svetlana Nikoulina, PhD – Director of Preclinical Research, SanRx: Leader in pipeline innovation and research strategy.

## Track Record

This diverse team boasts a proven history of excellence in immunology, pharmacology, oncology, chemistry, and clinical research. Together, they brought the expertise needed to drive ImmunoFolate's success in both development and commercialization.

---



# Market Opportunity

## Global Nutraceutical Market Size

- Projected at over \$600 billion by 2027.

## Target Audience

- Healthcare providers, immune-conscious consumers, and pharmaceutical distributors.

## Distribution Channels

- Retail pharmacies, online platforms, and strategic healthcare partnerships.
-

# Vision and Impact

## Mission

To revolutionize immune health and provide science-backed solutions for disease prevention and recovery.

## Impact

- Accelerated recovery from illnesses.
  - Potential future applications in cancer therapy.
  - Enhanced quality of life for users.
-

# Clinical Potential

## Emerging Applications

- Research indicates ImmunoFolate may combat cancer cells.
- Future clinical trials will validate its effectiveness in oncology.

**Thank you**

**Contact**

Phillip B.B. Moheno, PhD | +1 858 344 9778

---